BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis

The anti-inflammatory and immunomodulatory abilities of oral selective phosphodiesterase 4 (PDE4) inhibitors enabled the approval of roflumilast and apremilast for use in chronic obstructive pulmonary disease and psoriasis/psoriatic arthritis, respectively. However, the antifibrotic potential of PDE...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrmann, Franziska Elena, Hesslinger, Christian, Wollin, Lutz, Nickolaus, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065678/
https://www.ncbi.nlm.nih.gov/pubmed/35517783
http://dx.doi.org/10.3389/fphar.2022.838449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065678/
https://www.ncbi.nlm.nih.gov/pubmed/35517783
http://dx.doi.org/10.3389/fphar.2022.838449

Ejemplares similares